EMA Focuses on Greater International Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Focuses on Greater International Collaboration


Pharmaceutical Technology Europe


References

1. EMA website, "Partners & Networks," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

2. EMA website, "Road Map to 2015," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

3. K. Tadano, "PMDA's International Strategic Plan and its Implementation" (PMDA website), http://www.pharm.kitasato-u.ac.jp/, accessed 7 Sept. 2012.

4. Centre for Innovation in Regulatory Science (CIRS) website, "May 2012 Slide of the Month," http://cirsci.org/, accessed 7 Sept. 2012.

5. EMA website, "Report on interactions between the Japanese Ministry of Health, Labour and Welfare (MHLW)/Pharmaceuticals and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA)," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

6. Y. Hayashi, "EU, USA and Japan (II)– Reports from Regulators on Exchange Assignments" (PMDA website), http://www.pmda.go.jp/, accessed 7 Sept. 2012.

7. EMA website, "European Union — Japan orphan medicines cooperation". http://www.ema.europa.eu/, accessed 7 Sept. 2012.

8. EC website, "Medicines Regulation: Transatlantic Administrative Simplification Action Plan," http://ec.europa.eu/, accessed 7 Sept. 2012.

9. EMA website, "Enhancing GMP Inspection Cooperation Between the EMA and FDA," http://www.ema.europa.eu/, accessed 10 Sept. 2012.

10. WHO website, "Essential medicines for children". http://www.who.int/, accessed 7 Sept. 2012.

11. E. Silverman, "Clinical Trial Deaths In India Dropped" (Pharmalot website, 2012), http://www.pharmalot.com/, accessed 7 Sept. 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here